Gómez-Revuelta Marcos, Fernández-Rodríguez María, Boada-Antón Laura, Vázquez-Bourgon Javier
Department of Psychiatry, School of Medicine, University Hospital Marqués de Valdecilla-IDIVAL, University of Cantabria, Avda. Valdecilla nº25, Santander, Cantabria 39008, Spain.
Department of Anaesthesiology and Reanimation, Sierrallana Hospital, Torrelavega, Spain.
Ther Adv Psychopharmacol. 2020 Dec 23;10:2045125320981498. doi: 10.1177/2045125320981498. eCollection 2020.
Ketamine's pharmacological profile makes it an interesting and useful drug to challenge treatment-resistant-depression (TRD). Emerging adverse events associated with single-slow-sub-anaesthetic doses for the treatment of depression are common, although generally transient and self-limited. Nevertheless, data on the safety of this practice are scarce. Thus, it seems timely before ketamine is used for clinical treatment of depression to recommend careful monitoring and reporting of all potential adverse events related to ketamine administration. Here, we describe a case of apnea during slow sub-anaesthetic infusion of intravenous ketamine for the treatment of resistant depression. As far as we are concerned, this is an uncommon, previously unreported, and potentially severe adverse event that clinicians should be aware of, and specific management measures should be implemented.
氯胺酮的药理学特性使其成为一种用于挑战难治性抑郁症（TRD）的有趣且有用的药物。尽管单次缓慢亚麻醉剂量用于治疗抑郁症时出现的新的不良事件很常见，且通常是短暂的和自限性的，但关于这种治疗方法安全性的数据却很稀少。因此，在氯胺酮用于抑郁症临床治疗之前，建议仔细监测和报告所有与氯胺酮给药相关的潜在不良事件似乎很及时。在此，我们描述了一例在缓慢亚麻醉静脉输注氯胺酮治疗难治性抑郁症期间发生呼吸暂停的病例。就我们所知，这是一种罕见的、以前未报告过的且可能严重的不良事件，临床医生应予以关注，并应实施具体的管理措施。
